ClinicalTrials.gg
CompletedNCT01328938Updated Nov 6, 2013

GCPGC in Chemotherapy-induced Neutropenia

A Phase 2/3 interventional study of GCPGC 3.6mg and GCPGC 6mg in Chemotherapy Induced Neutropenia, sponsored by Green Cross Corporation. Completed at 15 sites in Korea, Republic of. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-11-06.

Sponsored by Green Cross Corporation · Phase 2/3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
177
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 33 studies testing pegfilgrastim in Neutropenia — none open to participants now, none under way, none of them phase 3. pegfilgrastim · Neutropenia.

Enrollment
10th of 28
177 · median 121
Started
2010
with 1 other
Phase 2/3
Only one
of the 33
Registered
17th of 33
by date

Among the 33 studies testing pegfilgrastim in Neutropenia, this one is the 10th largest by enrollment of the 28 interventional ones that give a count, is one of 2 that started in 2010, is the only one in phase 2/3, and was the 17th registered.

Neutropenia

316 studies on the registry are indexed under Neutropenia; 42 are open to participants now.

Browse Neutropenia studies →

Open to participants now

None of the 33 studies testing pegfilgrastim in Neutropenia is open now. The open studies under Neutropenia, anywhere →

About pegfilgrastim

pegfilgrastim: first FDA approval 2002 (NEULASTA), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 24 Neutropenia studies recruiting now, 12 (50%) set no upper age limit and 12 (50%) stop at 75 or younger; 11 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 33 studies testing pegfilgrastim in Neutropenia as a file.
02

Study summary

This study is adaptive design and it consists of stage I and stage II.

Stage I is multi-center, parallel-group, single-blind, phase II study to determine the adequate dose of GCPGC in chemotherapy-induced neutropenia. 2 Different doses of GCPGC will be investigated in a total of 60 Breast cancer patients who are receiving chemotherapy.

Stage II is multi-center, parallel-group, double-blind,phase III study to evaluate the efficacy and safety of once per cycle GCPGC in chemotherapy-induced neutropenia compared to Neulasta (pegfilgrastim). A total of 120 patients receiving chemotherapy will participate into this phase.

Read the detailed description

GCPGC ia a solution for containing pegfilgrastim. Pegfilgrastim is a covalent conjugate of recombinant human granulocyte colony-stimulating factor (G-CSF) with a polyethylene glycol (PEG) which has long half life compared to filgrastim, resulting in dosing advantage.

03

Conditions studied

  • Chemotherapy Induced Neutropenia

Browse trials for

Keywords

  • Pegfilgrastim
  • neutropenia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women(≥ 18 years old) diagnosed with breast cancer who are receiving chemotherapy inducing neutropenia
  • body weight of 45kg and more
  • performance status 2 and less
  • ≥1,500mm3 and ≥100,000/mm3
  • of 3 months and more
  • given written

Exclusion criteria

Exclusion Criteria:

  • had previous exposure to pegfilgrastim or filgrastim
  • had received systemic antibiotics within 72hrs of chemotherapy
  • prior total cumulative lifetime exposure to doxorubicin more than 240 mg/m or epirubicin more than 600 mg/m
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
177 participants (actual)

Study arms

  • Experimental
    Stage I - Arm I: GCPGC I (3.6mg)

    GCPGC 3.6mg, sc, once at Day 2 per cycle (in patients receiving chemotherapy at Day 1)

    Biological: GCPGC 3.6mg

  • Experimental
    Stage I - Arm II: GCPGC II (6mg)

    GCPGC 6mg, sc, once at Day 2 per cycle (in patients receiving chemotherapy at Day 1)

    Biological: GCPGC 6mg

  • Experimental
    Stage II - Arm I: GCPGC

    GCPGC 6mg, sc, once at Day 2 per cycle (in patients receiving chemotherapy at Day 1). The recommended dose in Stage II was determinated as GCPGC 6mg in Stage I.

    Biological: GCPGC 6mg

  • Active comparator
    Stage II - Arm II: Neulasta

    Neulasta 6mg, sc, once at Day 3 per cycle (in patients receiving chemotherapy at Day 1)

    Biological: Neulasta (pegfilgrastim) 6mg

Interventions

  • BiologicalGCPGC 3.6mg

    Stage I:Single blinded

    Also known as: Pegfilgrastim

  • BiologicalGCPGC 6mg

    Stage I: Single blinded;

    Also known as: Pegfilgrastim

  • Stage II: Active comparator, double blinded

  • BiologicalGCPGC 6mg

    Experimental: Stage II

    Also known as: Pegfilgrastim

06

What researchers measure

Primary outcomes

  1. Duration of grade 4 neutropenia(ANC<500mm3) for cycle 1

    Stage I: The difference in mean duration of grade 4 neutropenia between GCPGC 3.6mg and GCPGC 6mg is measured by check ANC in cycle I. Stage II : The difference in mean duration of grade 4 neutropenia between GCPGC which dose was determined at Stage I and Neulasta is measured by check ANC in cycle 1.

    Time frame: in cycle 1

Secondary outcomes

  1. Time to ANC recovery (≥2,000/mm3) after nadir in cycle 1

    Time frame: in cycle 1

  2. Depth of ANC nadir in cycle 1

    Time frame: in cycle 1

  3. Rates of Febrile neutropenia in all cycles

    Stage I: only in cycle 1; Stage II: in all cycles

    Time frame: in all cycles

  4. Rates of severe neutropenia persisting more than 3 days in cycle 1 (only for Stage II)

    Time frame: in cycle 1

  5. ANC values at Day 7 in all cycles (only for Stage II)

    Time frame: Day 7 in alll cycles

  6. Rates of delay or dose-reduction of chemotherapy due to neutropenia (only for Stage II)

    Time frame: all cycles

  7. Number of hospitalization due to febrile neutropenia in cycle 2 and after (only for Stage II)

    Time frame: in clycle 2-6

  8. Number of intravenous antimicrobial treatments due to febrile neutropenia

    Time frame: in all cycles

Other outcomes

  1. Incidence of antibody development in patients receiving GCPGC compared to Neulasta

    Time frame: 3 months after last treatment

  2. Vital sign, Physical examination, Laboratory tests, Occurrence of adverse reactions

    Time frame: in all cycles

07

Study locations

15 sites
  • Chungbuk National University Hospital
    Chungju, Chungchungbuk, Korea, Republic of
  • National Cancer Center
    Ilsan, KyungKi, Korea, Republic of
  • Gachon University Gil Hospital
    Incheon, KyungKi, Korea, Republic of
  • Seoul National University Bundang Hospital
    Sungnam, Kyungki, Korea, Republic of
  • Keimyung University Dongsan medical Center
    Daegu, Korea, Republic of
  • Pusan National University Hospital
    Pusan, Korea, Republic of
  • Chung-Ang University Hospital
    Seoul, Korea, Republic of
  • Inha University Hospital
    Seoul, Korea, Republic of
  • Konkuk University Medical Center
    Seoul, Korea, Republic of
  • Kyung Hee University Medical Center
    Seoul, Korea, Republic of
  • Seoul Asan Medical Center
    Seoul, Korea, Republic of
  • Seoul National University Hospital
    Seoul, Korea, Republic of
  • Seoul St.Mary's Hospital
    Seoul, Korea, Republic of
  • SMG-SNU Boramae Medical Center
    Seoul, Korea, Republic of
  • Ulsan University Hospital
    Ulsan, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2010, a primary completion of Nov 2012 and a completion of May 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2011
First posted
Apr 5, 2011
Start
Oct 2010
Primary completionActual
Nov 2012
CompletionActual
May 2013
Last update
Nov 6, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 6, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01328938
Collaborators
Symyoo
Responsible party
Sponsor
First posted
Apr 5, 2011
Start date
Oct 2010
Primary completion
Nov 2012
Completion
May 2013
Last update
Nov 6, 2013

Study contacts

Do-Youn Oh, M.D., Ph.D.
principal investigator · Seoul National University Hospital
Chang-Hee Lee, M.D., Ph.D.
study director · Green Cross Corporation
Seock-Ah Im, M.D., Ph.D.
principal investigator · Seoul National University Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegfilgrastim

Start the discussion